Benefits of a nurse-led home injection service for acromegaly patients treated with somatuline autogel.
Acromegaly
Adherence
Somatostatin analogues
Treatment
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
02
08
2020
accepted:
13
10
2020
pubmed:
25
10
2020
medline:
9
7
2021
entrez:
24
10
2020
Statut:
ppublish
Résumé
The aim of this study is to assess the benefits of a nurse-led home injection service for somatuline autogel-treated patients with acromegaly, including the adherence to treatment and disease control. Historical prospective data of all patients with acromegaly initiating somatuline autogel between November 14, 2000, and March 9, 2020, who voluntarily enrolled in the nurse-led home injection service between January 1, 2018 and June 30, 2020. Adherence to treatment was calculated as the number of administered injections divided by the number of expected injections during the follow-up period. Excellent adherence to treatment was defined when >90% of scheduled injections were administered, while low adherence was defined when patients received <80% of expected injections. The primary outcome was the adherence to treatment. The cohort included 88 patients (mean age ± SD, 59.8 ± 14.9 years, 53% men). Average adherence to treatment was 93 ± 8% (range 62-100%). Excellent adherence was documented in 65 participants (74%), of which 29 patients (33%) received all scheduled injections. Low adherence to treatment was recorded in seven patients (8%). Average adherence was high independent of gender, age, prior surgery, or radiation therapy, or whether somatuline autogel was used as monotherapy or in combination regimens. However, excellent adherence decreased with increased somatuline dose and with dosing interval of 21 days. Average adherence was slightly higher in patients with biochemically controlled acromegaly. A nurse-led home injection service for somatuline autogel injections is associated with high adherence to treatment. Establishing such a program globally may lead to better adherence to treatment and improved disease control.
Identifiants
pubmed: 33098539
doi: 10.1007/s12020-020-02529-5
pii: 10.1007/s12020-020-02529-5
doi:
Substances chimiques
Peptides, Cyclic
0
lanreotide
0G3DE8943Y
Somatostatin
51110-01-1
Insulin-Like Growth Factor I
67763-96-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
453-458Références
K.E. O’Reilly, F. Rojo, Q.B. She et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66(3), 1500–1508 (2006). https://doi.org/10.1158/0008-5472.CAN-05-2925
doi: 10.1158/0008-5472.CAN-05-2925
pubmed: 16452206
pmcid: 3193604
S. Melmed, Acromegaly. N. Engl. J. Med. 355, 2558–2573 (2006). https://doi.org/10.3828/rs.2012.10
doi: 10.3828/rs.2012.10
pubmed: 17167139
L. Katznelson, E.R. Laws, S. Melmed et al. Acromegaly: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99(11), 3933–3951 (2014). https://doi.org/10.1210/jc.2014-2700
doi: 10.1210/jc.2014-2700
pubmed: 25356808
J.D. Carmichael, V.S. Bonert, M. Nuño, D. Ly, S. Melmed, Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J. Clin. Endocrinol. Metab. 99(5), 1825–1833 (2014). https://doi.org/10.1210/jc.2013-3757
doi: 10.1210/jc.2013-3757
pubmed: 24606084
pmcid: 4010703
J. Schopohl, C.J. Strasburger, D. Caird et al. Efficacy and acceptability of lanreotide autogel® 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR. Exp. Clin. Endocrinol. Diabetes 119(3), 156–162 (2011). https://doi.org/10.1055/s-0030-1267244
doi: 10.1055/s-0030-1267244
pubmed: 21086246
M.H. Gurel, Y. Han, A.L. Stevens, A. Furtado, D. Cox, Treatment adherence and persistence with long-acting somatostatin analog therapy for the treatment of acromegaly: a retrospective analysis. BMC Pharm. Toxicol. 18(1), 22 (2017). https://doi.org/10.1186/s40360-017-0124-y
doi: 10.1186/s40360-017-0124-y
C. Álvarez-Escolá, E.M. Venegas-Moreno, J.A. García-Arnés et al. ACROSTART: a retrospective study of the time to achieve hormonal control with lanreotide autogel treatment in Spanish patients with acromegaly. Endocrinol. Diabetes Nutr. 66(5), 320–329 (2019). https://doi.org/10.1016/j.endien.2019.05.002
doi: 10.1016/j.endien.2019.05.002
pubmed: 30773338
I. Bernabéu, C. Fajardo, M. Marazuela et al. Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly. Endocrine. 2020. https://doi.org/10.1007/s12020-020-02424-z
C.N. Jayasena, A.N. Comninos, H. Clarke, M. Donaldson, K. Meeran, W.S. Dhillo, The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly. Clin. Endocrinol. 75(2), 220–225 (2011). https://doi.org/10.1111/j.1365-2265.2011.04019.x
doi: 10.1111/j.1365-2265.2011.04019.x